Compare Agilent Technologies Inc (A) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs Las Vegas Sands Corp. — how do they compare? Agilent Technologies Inc trades at $148.58 (market cap $42.22B), while Las Vegas Sands Corp. trades at $45.52 (market cap $29.44B). The key difference: Agilent Technologies Inc is the larger of the two by market cap, and Las Vegas Sands Corp. pays the higher dividend (2.64%). Which is the better fit depends on your goals.
| A | LVS | |
|---|---|---|
Market Cap | $42.22B | $29.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $157.20 | $69.49 |
52-Week Low | $110.24 | $44.78 |
Enterprise Value | $43.77B | $41.33B |
Dividend Yield | 0.68% | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $148.72, up 1.88% with strong analyst support (77.5% buy ratings). The stock shows bullish technical momentum above key support levels, supported by consistent revenue around $6.9B and robust profitability with 19.55% net margins. Recent FDA approvals for diagnostic tests and the Biocare Medical acquisition enhance growth prospects in biopharma markets.
Outlook remains positive with a $154.90 consensus price target offering 4% upside, though high P/E of 30.02 poses valuation risk. Key catalysts include Q2 2026 earnings due August 26 and AI-driven lab expansion, while overbought RSI levels near 92 suggest near-term consolidation potential.
LVS trades at $45.46, down 0.68% today, with a bearish technical signal from moving averages. The company reported mixed Q2 2026 earnings, missing EPS estimates at $0.59 versus $0.757 expected, but revenue growth remains robust with 2025 revenue at $13.02B. Analyst consensus is strongly bullish with a $60.75 price target and no sell ratings among 49 analysts. Recent news highlights corporate responsibility efforts and operational achievements in Macao.
The outlook is supported by strong fundamentals including a 12.59% net income margin and positive cash flow trends, but risks include high debt levels and competitive pressures. Upside potential exists if earnings rebound in Q3, aligning with analyst optimism, though technical weakness near support at $44 requires monitoring for stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
